CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Izotropic Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Izotropic Corp
Suite 424, 800-15355 24th Avenue
Phone: (604) 542-9458p:604 542-9458 SURREY, BC  V4A 2H9  Canada Ticker: IZOIZO

Business Summary
Izotropic Corporation is a Canada-based research and development company. The Company is engaged in cancer research and early detection for breast cancer. The Company commercials a dedicated breast CT imaging platform, IzoView, for the detection and diagnosis of breast cancers. IzoView Breast CT system is an indispensable tool for improving the outcomes of breast cancer.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
7/31/20224/30/2022Yes----

Business Names
Business Name
IZO
Izotropic Imaging Corp

General Information
Outstanding Shares: 49,028,954 (As of 7/31/2022)
Stock Exchange: CNQ
Fax Number: (604) 542-9458


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 7, 2022